Subarachnoid hemorrhage (SAH) is one of the most devastating forms of stroke with the highest immediate mortality of all strokes (exceeding 30%) and leading to severe disability for those who survive. This leads to a significant number of potential life years lost, creating a financial and intellectual loss to society. In addition to the initial insult, delayed cerebral ischemia (DCI) secondary to arterial vasospasm and chronic hydrocephalus requiring permanent CSF diversion are other complicating factors of subarachnoid hemorrhage. To date, aside from nimodipine, there are no preventative options for DCI or chronic hydrocephalus in SAH patients. With such strong data involving DFO use in SAH animal models and recent human data with DFO use in intracranial hemorrhage (ICH), a multicenter, randomized Phase I/II trial to determine the safety and futility of deferoxamine treatment in the human SAH population is expected provide data that changes the current treatment methodology of subarachnoid hemorrhage and improves patient functional outcomes. This proposed trial will evaluate the safety and futility of clinical deferoxamine use in SAH and could lead to changes in the current SAH treatment algorithm. If this trial is successful, it will generate crucial preliminary data that will support further clinical trial grant applications for a Phase III trial with a much larger sample size through the NIH/NINDS (USA) and National Science Foundation (China).